{"groups":[{"description":"NEOADJUVANT: Patients receive atezolizumab IV over 30-60 minutes, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 2 hours on day 1. Cycles repeats every 21 days for 4 cycles in the absence of disease progression or unexpected toxicity.\n\nSURGERY: Within 21-90 days after completion of neoadjuvant therapy, patients undergo extrapleural pneumonectomy (EPP) or pleurectomy/decortication (PD). Patients who undergo EPP will then undergo radiation therapy.\n\nMAINTENANCE: Within 90 days after completion of either PD or radiation (post-EPP), patients receive atezolizumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 1 year in the absence of disease progression or unexpected toxicity.","id":"FG000","title":"Treatment (Chemotherapy, Surgery +/- RT, Maintenance)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Progression/Relapse"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"28"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"21"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"7"}],"type":"NOT COMPLETED"}],"title":"Neoadjuvant"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Other - Not Protocol Specified"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"19"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"16"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"NOT COMPLETED"}],"title":"Surgery"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Refusal Unrelated to Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"10"}],"type":"Progression/Relapse"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"15"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"11"}],"type":"NOT COMPLETED"}],"title":"Maintenance"}],"preAssignmentDetails":"29 participants were registered to the study, 1 participant was ineligible, so 28 participants received protocol treatment for Step 1, Neoadjuvant."}